Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pathology and Genetics in a Global Cohort of Parkinsonian Disorders.

JAMA neurology·2026
Same author

GWAS on short tandem repeats identifies genetic mechanisms in Alzheimer's disease.

Nature communications·2026
Same author

Pathology and genetics in a global cohort of Parkinsonian Disorders.

medRxiv : the preprint server for health sciences·2026
Same author

Robust immunohistochemical detection of α-synuclein, tau and amyloid-β in human brain tissue archived for up to 78 years.

Free neuropathology·2026
Same author

Wide complex tachycardia in the emergency department: an updated approach to diagnosis and management.

Emergency medicine practice·2026
Same author

Epigenetic control of microglial developmental milestones from proliferative progenitors to efficient phagocytes.

Research square·2026
Same journal

Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom-Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Aya Abdallah1, Robert Allen1, Dominik Domanski1

  • 1University of Oxford, Oxford, Oxfordshire, United Kingdom.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary
This summary is machine-generated.

This study analyzed cerebrospinal fluid (CSF) from the OPTIMA cohort to identify biomarkers for Alzheimer's Disease (AD) and mixed pathologies. Findings highlight differences in biomarker concentrations between living and post-mortem samples, impacting diagnostic utility.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neuroscience
  • Biomarker Discovery
  • Gerontology

Background:

  • Alzheimer's Disease (AD) involves amyloid plaques and neurofibrillary tangles, often co-occurring with other pathologies like dementia with Lewy bodies (DLB) and Limbic-predominant age-related TDP-43 encephalopathy (LATE).
  • Accurate diagnosis and patient stratification require biomarkers that capture these mixed pathologies, beyond established amyloid and tau markers.
  • The OPTIMA cohort provides a valuable longitudinal resource for studying neurodegenerative diseases.

Purpose of the Study:

  • To integrate high-throughput brain pathology data with biofluid assays and proteomics.
  • To generate novel biomarkers for stratifying patients with AD and mixed pathologies.
  • To characterize the Amyloid, Tau, and Neurodegeneration (ATN) status in CSF samples from the OPTIMA cohort.

Main Methods:

  • Analysis of baseline lumbar CSF samples from 332 participants in the OPTIMA cohort, including pure AD, mixed AD+DLB/LATE, and healthy controls.
  • Quantification of pTau181, t-Tau, Aβ42, and Aβ-40 concentrations using EuroImmun ELISAs.
  • Inclusion of post-mortem ventricular CSF data from a small subset of cases for comparative analysis.

Main Results:

  • Characterization of ATN status in CSF samples from the OPTIMA cohort.
  • Post-mortem ventricular CSF showed significantly higher pTau181 levels compared to lumbar CSF.
  • Aβ-42 levels were undetectable in post-mortem ventricular CSF samples.

Conclusions:

  • The OPTIMA cohort is crucial for advancing diagnostics and treatments for neurodegenerative diseases.
  • Concentration discrepancies in ATN-defining proteins between post-mortem ventricular CSF and ante-mortem lumbar CSF may limit the use of post-mortem CSF as technical controls.
  • Further research is needed to develop reliable cross-matrix biomarkers for mixed pathologies.